Current Clinical Trials

The prognosis for any treated cancer patient with progressing, recurring, or relapsing extrahepatic bile duct cancer is poor. Deciding on further treatment depends on many factors, including prior treatment and site of recurrence, as well as individual patient considerations. Relief of recurrent jaundice will usually improve quality of life. Clinical trials are appropriate and should be considered when possible.[1,2]

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with recurrent extrahepatic bile duct cancer ¹. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI Web site ².

References

1. Bartlett DL, Ramanathan RK, Deutsch M: Cancer of the biliary tree. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds.: Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2005, pp 1009-31. 
   
   
2. Nordback IH, Pitt HA, Coleman J, et al.: Unresectable hilar cholangiocarcinoma: percutaneous versus operative palliation. Surgery 115 (5): 597-603, 1994.  [PUBMED Abstract]